Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas

Cancer

Volumn 106, Issue 9, 2006, Pages 1940-1949

  Le, Quynh Thu ^a   Taira, Al ^a   Budenz, Sherie ^b   Dorie, Mary Jo ^a   Goffinet, Don R ^a   Fee, Willard E ^a   Goode, Richard ^a   Bloch, Daniel ^a   Koong, Albert ^a   Brown, J Martin ^a   Pinto, Harlan A ^b,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Chemotherapy; Head and neck cancers; Hypoxia; Radiotherapy; Tirapazamine

Indexed keywords

CISPLATIN; FLUOROURACIL; TIRAPAZAMINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; ESOPHAGUS STRICTURE; FEMALE; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HEARING LOSS; HEART DISEASE; HEART INFARCTION; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOTHYROIDISM; INFECTION; LUNG DISEASE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OXYGEN TENSION; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TUMOR VOLUME; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SURVIVAL RATE; TREATMENT OUTCOME; TRIAZINES;

EID: 33646353445     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21785     Document Type: Article

References (33)

1. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and surveys of existing data. Int J Radiat Oncol Biol Phys. 1984;10:695-712.
2. Teicher BA, Holden SA, Al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in-vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50:3339-3344.
3. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113-117.
4. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57:39-43.
5. Rudat V, Vanselow B, Wollensack P, et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol. 2000;57:31-37.
6. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 2002;62:5248-5253.
7. Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer. 1993;67:1163-1170.
8. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990;50:7745-7749.
9. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 1993;53:4633-4636.
10. Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol. 1997;39:361-366.
11. Lee DJ, Trotti A, Spencer S, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int J Radiat Oncol Biol Phys. 1998;42:811-815.
12. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:535-542.
13. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized Phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.
14. Pinto HA, Le QT, Terris DJ, Bloch D, Goffinet DR, Brown JM, Randomized trial of tirapazamine/cisplatin/fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced resectable head and neck cancer (abstract 904). Proc Am Soc Clin Oncol. 2002;21:227a.
15. Terris DJ, Dunphy EP. Oxygen tension measurements of head and neck cancers. Arch Otolaryngol Head Neck Surg. 1994;120:283-287.
16. Olive PL. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs. Acta Oncol. 1995;34:301-305.
17. Dorie MJ, Kovacs MS, Gabalski EC, et al. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia. 1999;1:461-467.
18. Le QT, Kovacs MS, Dorie MJ, et al. Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2003;56:375-383.
19. Star-Lack J, Spielman D, Adalsteinsson E, Kurhanewicz J, Terris DJ, Vigneron DB. In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors. J Magn Reson. 1998;133:243-254.
20. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the International CATA-PULT I Study Group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 2000;18:1351-1359.
21. Shulman LN, Boswell L, Riese N, et al. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys. 1999;44:349-353.
22. National Cancer Institute. Common toxicity criteria. Available at URL: http://ctep.info.nih.gov [accessed December 2003].
23. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
24. Kaplan ES, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-482.
25. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
26. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638-648.
27. Eschwege F, Sancho-Garnier H, Chassagne D, et al. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas [see comments]. Int J Radiat Oncol Biol Phys. 1997;39:275-281.
28. Lee DJ, Cosmatos D, Marcial VA, et al. Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas [see comments]. Int J Radiat Oncol Biol Phys. 1995;32:567-76.
29. Overgaard J, Hansen HS, Anderson AP, et al. Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA study. Int J Radiat Oncol Biol Phys. 1989;16:1065-1068.
30. Fazekas JT, Pajak TF, Wasserman T, et al. Failure of misonidazole- sensitized radiotherapy to impact upon outcome among Stage III-IV squamous cancers of the head and neck. Int J Radiat Oncol Biol Phys. 1987;13:1155-1160.
31. Chao KS. Protection of salivary function by intensity-modulated radiation therapy In patients with head and neck cancer. Semin Radiat Oncol. 2002;12(1 Suppl 1):20-25.
32. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57:49-60.
33. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.